CureVac (NASDAQ:CVAC - Get Free Report) is set to release its earnings data before the market opens on Tuesday, November 12th. Analysts expect CureVac to post earnings of $0.67 per share for the quarter.
CureVac (NASDAQ:CVAC - Get Free Report) last posted its quarterly earnings results on Thursday, August 15th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.06). The business had revenue of $15.55 million during the quarter, compared to analysts' expectations of $10.07 million. CureVac had a negative net margin of 422.66% and a negative return on equity of 57.18%. On average, analysts expect CureVac to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
CureVac Trading Up 0.4 %
Shares of NASDAQ:CVAC traded up $0.01 during trading on Friday, reaching $2.84. 716,344 shares of the stock were exchanged, compared to its average volume of 848,120. The firm's 50-day moving average price is $2.95 and its 200 day moving average price is $3.25. The firm has a market cap of $635.82 million, a price-to-earnings ratio of -2.12, a price-to-earnings-growth ratio of 1.92 and a beta of 2.61. CureVac has a 12-month low of $2.21 and a 12-month high of $6.30. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.28 and a current ratio of 2.29.
Wall Street Analysts Forecast Growth
Separately, JMP Securities restated a "market outperform" rating and issued a $16.00 target price on shares of CureVac in a research note on Monday, September 16th.
View Our Latest Stock Report on CureVac
CureVac Company Profile
(
Get Free Report)
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
Featured Articles
Before you consider CureVac, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.
While CureVac currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
